The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy

Condition(s) targeted: Helicobacter Pylori

Intervention: FP-10 (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: Hamamatsu University

Official(s) and/or principal investigator(s):
Takahisa Furuta, MD, PhD, Study Director, Affiliation: Center for Clinical Research, Hamamatsu University School of Medicine
Kazunrai Murakami, MD, PhD, Study Director, Affiliation: Department of Gastroenterology, Oita University Faculty of Medicine
Toshio Fujioka, MD, PhD, Study Chair, Affiliation: Oita University

Overall contact:
Takahisa Furuta, MD, PhD, Phone: 81-53-435-2850, Email: furuta@hama-med.ac.jp

FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Official title: The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome: The effect of FP-01 on the eradication rates of H. pylori infection by a triple therapy

Secondary outcome: The effect o FP-10 on the eradication rates of clarithromycin-sensitive and -resistant strains of H. pylori by a triple therapy

Detailed description:

H. pylori - positive patients older than 15 years of age with gastritis, gastric ulcer,

duodenal ulcer, or gastroduodenal ulcer are invited to participate in the study. These patients had endoscopically and histologically proven ulcers or active chronic gastritis and are all H. pylori-positive. Written informed consent to participation must be obtained from each patient before the study.

During gastroduodenoscopy, biopsy specimens obtained from both the antrum and the corpus of the greater curvature are subjected to the bacterial susceptibility to clarithromycin by culture test or measurements of 23S rRNA mutations at positions 2142 and 2143 (from adenine to guanine).

Patients are treated with 30 mg of lansoprazole bid, 200 mg of clarithromycin bid, and 750 mg of amoxicillin bid for one week. In addition, they take placebo bid, FP10 1 g bid, or FP-10 2 g bid (2 hour after breakfast and at the bed time) for the same one week. Administration of placebo, FP-10 1 g or FP-10 2 g are performed in a double blinded manner.

Eradication of H. pylori was confirmed by a 13C-urea breath test performed one month after eradication therapy. Throughout the study period, the investigators involved in the assessment of H. pylori eradication are blinded to susceptibility to clarithromycin H. pylori strains.

Minimum age: 15 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

H. pylori-positive patients who have never undergo the H. pylori eradication therapy -

Exclusion Criteria:

Patients not infected with H. pylori, Patients who are allergic to amoxicillin, clarithromycin, lansoprazole, 13C-urea, or milk casein

-

Takahisa Furuta, MD, PhD, Phone: 81-53-435-2850, Email: furuta@hama-med.ac.jp

University Hospital of Oita University Faculty of Medicine, Oita 879-5593, Japan; Recruiting
Kazunari Murakami, MD, PhD, Phone: 81-97-586-6193, Email: murakam@med.oita-u.ac.jp
Kazunari Murakami, MD, PhD, Principal Investigator

Oita Kouseiren Tsurumi Hospital, Beppu, Oita 874-8585, Japan; Recruiting
Takayuki Nagai, MD. PhD, Phone: 81-977-23-7111, Email: ikyoku@ok-tsurumi.com
Takayuki Nagai, MD, PhD, Principal Investigator

University Hospital of Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan; Recruiting
Takahisa Furuta, MD, PhD, Phone: 81-53-435-2850, Email: furuta@hama-med.ac.jp
Takahisa Furuta, MD, PhD, Principal Investigator
Naohito Shirai, MD, PhD, Sub-Investigator
Mitsushige Sugimoto, MD, Sub-Investigator

Nakajima Clinic, Kakegawa, Shizuoka 436, Japan; Recruiting
Hiroshi Nakamura, MD, PhD, Phone: 81-537-22-6819, Email: mdnakajima@mail.wbs.ne.jp
Hiroshi Nakajima, MD, PhD, Principal Investigator

Matsushita Clinic, Hamamatsu, Shizuoka 433-8121, Japan; Recruiting
Fumiaki Matsushita, MD, PhD, Phone: 81-53-475-5225, Email: fmatsushita@mail.wbs.ne.jp
Fumiaki Matsushida, MD, PhD, Principal Investigator

Kumagai Clinic for Internal Medicine and Gastroenterology, Hamamatsu, Shizuoka 435-0006, Japan; Recruiting
Junichi Kumagai, MD, PhD, Phone: 81-53-422-2588, Email: jkuma@yr.tnc.ne.jp
Junichi Kumagai, MD, PhD, Principal Investigator

Senoo Clinic for Internal Medicine and Gastroenterology, Hamamatsu, Shizuoka 431-3125, Japan; Recruiting
Kazutaka Senoo, MD, Email: CBF00628@nifty.com
Kazutaka Senoo, MD, Principal Investigator

Related publications:

Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, Yoneyama M, Ohashi K, Ishizaki T, Hishida A. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.

Shirai N, Furuta T, Sugimoto M, Nakamura A. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy] Nippon Rinsho. 2005 Nov;63 Suppl 11:438-41. Japanese. No abstract available.

Okudaira K, Miura S, Furuta T, Sugimoto M, Shirai N. [Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection] Nippon Rinsho. 2005 Nov;63 Suppl 11:391-6. Japanese. No abstract available.

Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67.

Furuta T, Shirai N, Sugimoto M, Nakamura A, Okudaira K, Kajimura M, Hishida A. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharmacol Ther. 2005 Jul 1;22(1):67-74.

Okudaira K, Furuta T, Shirai N, Sugimoto M, Miura S. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Aliment Pharmacol Ther. 2005 Feb 15;21(4):491-7. Erratum in: Aliment Pharmacol Ther. 2005 Jun 1;21(11):1398.

Murakami K, Fujioka T. [Drug resistant H. pylori in Japan: general remarks] Nippon Rinsho. 2005 Nov;63 Suppl 11:198-202. Japanese. No abstract available.

Murakami K, Kodama M, Sato R, Okimoto T, Watanabe K, Fujioka T. Helicobacter pylori eradication and associated changes in the gastric mucosa. Expert Rev Anti Infect Ther. 2005 Oct;3(5):757-64.

Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Fujioka T, Kodama M, Kagawa J. Influence of anti-ulcer drugs used in Japan on the result of (13)C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol. 2003;38(10):937-41.

Hiramoto S, Itoh K, Shizuuchi S, Kawachi Y, Morishita Y, Nagase M, Suzuki Y, Nobuta Y, Sudou Y, Nakamura O, Kagaya I, Goshima H, Kodama Y, Icatro FC, Koizumi W, Saigenji K, Miura S, Sugiyama T, Kimura N. Melanoidin, a food protein-derived advanced maillard reaction product, suppresses Helicobacter pylori in vitro and in vivo. Helicobacter. 2004 Oct;9(5):429-35.

Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther. 2003 Jan;17(1):119-23.

Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J, Sato S, Abe H, Arita T. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2002 Nov;16(11):1933-8.

Murakami K, Nasu M. [Clarithromycin (CAM)] Nippon Rinsho. 2002 Feb;60 Suppl 2:667-70. Review. Japanese. No abstract available.

Murakami K, Nasu M. [Drug sensitivity test for Helicobacter pylori] Nippon Rinsho. 2002 Feb;60 Suppl 2:350-3. Review. Japanese. No abstract available.

Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents. 2002 Jan;19(1):67-70.

Asaka M, Satoh K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, Murakami K, Kimura K, Shimoyama T. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter. 2001 Sep;6(3):177-86.

Murakami K, Fujioka T, Kodama R, Kubota T, Tokieda M, Nasu M. Helicobacter pylori infection accelerates human gastric mucosal cell proliferation. J Gastroenterol. 1997 Apr;32(2):184-8.

Starting date: January 2006
Ending date: May 2006
Last updated: January 26, 2006